Loading...

ニュース

New drugs for Crohn's disease! Eu approves Skyrizi: The First specific IL-23 inhibitor for Crohn's Disease!

2022-11-25


New drugs for Crohn's disease! Eu approves Skyrizi: The First specific IL-23 inhibitor for Crohn's Disease!

Abbvie announced that the European Commission has approved a new indication for Skyrizi, its novel anti-inflammatory IL-23 inhibitor: Skyrizi 600mg intravenous induction and 360mg subcutaneous maintenance therapy were used to treat adults with moderate to severe active Crohn's disease who were under-responsive, unresponsive, or intolerant to conventional or biological therapies. It is worth mentioning that Skyrizi is the first specific IL-23 inhibitor approved for the treatment of CD in the European Union and the United States.

当社は、このウェブサイトの利用状況をより良く理解し、今後のウェブサイト訪問時の体験を向上させるために、クッキーを使用したいと考えています。この設定は、ブラウザの設定で変更できます。クッキーの使用に関する詳細については、当社の プライバシー ポリシー を参照してください。